Tag:

Boston Biomedical

Latest Headlines

Latest Headlines

PhIII flop for top Boston cancer stem cell program batters Dainippon Sumitomo

Over the long holiday weekend, Dainippon Sumitomo's shares took a beating--dropping 21% at one point, according to Bloomberg--as investors reacted to the news that BBI608 proved to be a dud in its most advanced trial for colorectal cancer.

Top 10 late-stage cancer drugs in 2012

Thousands of experimental meds are winding their way through various stages of clinical trials today, and the largest category among the contenders is cancer drugs.

Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout

Boston Biomedical's focus on targeting cancer stem cells has paid off.